Virtu Financial LLC Takes Position in Becton Dickinson and Co (NYSE:BDX)

Virtu Financial LLC acquired a new stake in shares of Becton Dickinson and Co (NYSE:BDX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,439 shares of the medical instruments supplier’s stock, valued at approximately $364,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in BDX. Morgan Stanley raised its holdings in shares of Becton Dickinson and by 66.7% during the 2nd quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock valued at $1,231,621,000 after buying an additional 1,955,095 shares during the period. Nuveen Asset Management LLC boosted its position in Becton Dickinson and by 12,995.3% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,429,875 shares of the medical instruments supplier’s stock worth $360,343,000 after acquiring an additional 1,418,956 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Becton Dickinson and by 33.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,152,328 shares of the medical instruments supplier’s stock valued at $544,452,000 after purchasing an additional 543,512 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Becton Dickinson and by 2.3% in the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock worth $5,800,769,000 after purchasing an additional 520,350 shares during the period. Finally, Stonehage Fleming Financial Services Holdings Ltd bought a new position in Becton Dickinson and in the 2nd quarter valued at about $101,966,000. 84.65% of the stock is currently owned by institutional investors and hedge funds.

In other news, CEO Vincent A. Forlenza sold 11,532 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the transaction, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP James C. Lim sold 9,299 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $263.53, for a total value of $2,450,565.47. Following the completion of the transaction, the executive vice president now directly owns 33,041 shares in the company, valued at $8,707,294.73. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,345 shares of company stock valued at $5,847,029. Corporate insiders own 0.12% of the company’s stock.

A number of equities analysts have issued reports on the company. KeyCorp decreased their price target on Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. Wells Fargo & Co lifted their price target on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th. Finally, Piper Jaffray Companies decreased their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $266.00.

NYSE:BDX opened at $255.73 on Wednesday. The firm’s 50-day moving average is $251.93 and its 200-day moving average is $249.17. The company has a market cap of $69.91 billion, a price-to-earnings ratio of 22.13, a PEG ratio of 1.82 and a beta of 1.07. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $264.74.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, topping analysts’ consensus estimates of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.52% and a net margin of 6.84%. The business had revenue of $4.58 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same period last year, the business earned $2.93 earnings per share. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. Equities analysts predict that Becton Dickinson and Co will post 12.57 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. Becton Dickinson and’s payout ratio is 26.37%.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: Key terms to understand channel trading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit